|
Lunsekimig Clinical Trials
4 actively recruiting trials across 4 locations
Also known as: SAR443765
Pipeline
Phase 2: 2Phase 3: 2
Top Sponsors
- Sanofi4
Indications
- Chronic Obstructive Pulmonary Disease2
- Asthma2
- COPD2
Saraland, Alabama1 trial
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
The Center for Clinical Trials - Saraland- Site Number : 8400096
Phase 2
Chandler, Arizona1 trial
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Chandler Clinical Research Trials- Site Number : 8400025
Phase 3
Tucson, Arizona1 trial
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Tucson Clinical Research Institute- Site Number : 8400006
Phase 3
Aurora, Colorado1 trial
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.
Allianz Research Institute - Aurora- Site Number : 8400026
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.